Conclusion Understanding changes in clinical characteristics and treatment patterns over time among new users of SGLT2i or GLP-1 RA in the US as described in this observational study is important to inform and contextualize future studies assessing cardiorenal outcomes for these and additional treatments, including finerenone, for individuals with CKD and type 2 diabetes
By curbing cravings and promoting a sense of fullness, Semaglutide supports gradual weight loss
Over the past 30years, gastrointestinal hormones have been increasingly understood to have an important role as regulators of appetite and energy balance in obese individuals
[10] Analyses of the SUSTAIN and PIONEER trial programs for semaglutide found no imbalance in cancer incidence across treatment groups
Alberti KG, Johnston DG, Gill A, Barnes AJ, Orskov H
"I loved to distract myself with people, food, drinking, problems I'd create," she admitted